Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1981 May;43(5):644–653. doi: 10.1038/bjc.1981.95

Immunofluorescent detection of hormone receptors in cutaneous melanocytic tumours.

A J Thompson, M G Cook, P G Gill
PMCID: PMC2010676  PMID: 6264940

Abstract

Immunofluorescent assessment of hormone receptors in melanocytic tumours is quite feasible without loss of diagnostic material, in contrast to the impracticability of quantitative biochemical assays. Using this method, oestrogen receptors were demonstrated in 4/6, and progesterone receptors in 3/5 patients with metastatic melanoma. Receptors were not found in 3 patients with primary cutaneous melanomas of the superficial spreading type. Progesterone receptors were present in the junctional component of a naevus from one healthy person.

Full text

PDF
644

Images in this article

648Fig. 1
on p.648
648Fig. 2
on p.648
649p649-a
on p.649
650Fig. 3
on p.650

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham G. E. Solid-phase radioimmunoassay of estradiol-17 beta. J Clin Endocrinol Metab. 1969 Jun;29(6):866–870. doi: 10.1210/jcem-29-6-866. [DOI] [PubMed] [Google Scholar]
  2. Chaudhuri P. K., Walker M. J., Briele H. A., Beattie C. W., Gupta T. K. Incidence of estrogen receptor in benign nevi and human malignant melanoma. JAMA. 1980 Aug 22;244(8):791–793. [PubMed] [Google Scholar]
  3. Cox R. I., Hoskinson R. M., Wong M. S. Antisera reactive directly to estrone sulfate. Steroids. 1979 May;33(5):549–562. doi: 10.1016/0039-128x(79)90035-7. [DOI] [PubMed] [Google Scholar]
  4. Creagan E. T., Ingle J. N., Green S. J., Ahmann D. L., Jiang N. S. Phase II study of tamoxifen in patients with disseminated malignant melanoma. Cancer Treat Rep. 1980 Feb-Mar;64(2-3):199–201. [PubMed] [Google Scholar]
  5. Fisher R. I., Neifeld J. P., Lippman M. E. Oestrogen receptors in human malignant melanoma. Lancet. 1976 Aug 14;2(7981):337–339. doi: 10.1016/s0140-6736(76)92592-7. [DOI] [PubMed] [Google Scholar]
  6. Hawkins R. A., Hill A., Freedman B. A simple method for the determination of oestrogen receptor concentrations in breast tumours and other tissues. Clin Chim Acta. 1975 Oct 15;64(2):203–210. doi: 10.1016/0009-8981(75)90202-8. [DOI] [PubMed] [Google Scholar]
  7. Horwitz K. B., Costlow M. E., McGuire W. L. MCF-7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids. 1975 Dec;26(6):785–795. doi: 10.1016/0039-128x(75)90110-5. [DOI] [PubMed] [Google Scholar]
  8. Lee S. H. Cellular estrogen and progesterone receptors in mammary carcinoma. Am J Clin Pathol. 1980 Mar;73(3):323–329. doi: 10.1093/ajcp/73.3.323. [DOI] [PubMed] [Google Scholar]
  9. McGuire W. L., Horwitz K. B., Zava D. T., Garola R. E., Chamness G. C. Hormones in breast cancer: update 1978. Metabolism. 1978 Apr;27(4):487–501. doi: 10.1016/0026-0495(78)90103-8. [DOI] [PubMed] [Google Scholar]
  10. Nenci I., Beccati M. D., Pagnini C. A. Estrogen receptors and post-receptor markers in human breast cancer: a reappraisal. Tumori. 1978 Apr 30;64(2):161–174. doi: 10.1177/030089167806400206. [DOI] [PubMed] [Google Scholar]
  11. Ojasoo T., Raynaud J. P. Unique steroid congeners for receptor studies. Cancer Res. 1978 Nov;38(11 Pt 2):4186–4198. [PubMed] [Google Scholar]
  12. Pertschuk L. P., Tobin E. H., Brigati D. J., Kim D. S., Bloom N. D., Gaetjens E., Berman P. J., Carter A. C., Degenshein G. A. Immunofluorescent detection of estrogen receptors in breast cancer. Comparison with dextran-coated charcoal and sucrose gradient assays. Cancer. 1978 Mar;41(3):907–911. doi: 10.1002/1097-0142(197803)41:3<907::aid-cncr2820410318>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  13. Pichon M. F., Milgrom E. Characterization and assay of progesterone receptor in human mammary carcinoma. Cancer Res. 1977 Feb;37(2):464–471. [PubMed] [Google Scholar]
  14. Rümke P., Persijn J. P., Korsten C. B. Oestrogen and androgen receptors in melanoma. Br J Cancer. 1980 Apr;41(4):652–656. doi: 10.1038/bjc.1980.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sadoff L., Winkley J., Tyson S. Is malignant melanoma an endocrine-dependent tumor? The possible adverse effect of estrogen. Oncology. 1973;27(3):244–257. doi: 10.1159/000224736. [DOI] [PubMed] [Google Scholar]
  16. Shaw H. M., Milton G. W., Farago G., McCarthy W. H. Endocrine influences on survival from malignant melanoma. Cancer. 1978 Aug;42(2):669–677. doi: 10.1002/1097-0142(197808)42:2<669::aid-cncr2820420238>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  17. Shiu M. H., Schottenfeld D., Maclean B., Fortner J. G. Adverse effect of pregnancy on melanoma: a reappraisal. Cancer. 1976 Jan;37(1):181–187. doi: 10.1002/1097-0142(197601)37:1<181::aid-cncr2820370126>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  18. Szego C. M. The lysosome as a mediator of hormone action. Recent Prog Horm Res. 1974;30(0):171–233. doi: 10.1016/b978-0-12-571130-2.50009-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES